MedTrace Logo

Effects of Intravenous Injection of Erythropoietin on Hepcidin Pharmacokinetics in Healthy Volunteers

NCT00687518 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2008-05-30

No results posted yet for this study

Summary

The aim of this study is to measure the variations of serum and urinary hepcidin levels following a single intravenous injection of erythropoietin in healthy volunteers. Hepcidin is a major regulator of iron homeostasis. It acts by binding on ferroportin, and limits cellular efflux of iron through enterocytes and macrophages. Anemia and hypoxia are known to modulate hepcidin synthesis. In these situations, erythropoietin synthesis is increased, so it can be postulated that erythropoietin could modulate hepcidin synthesis.

Conditions

  • Iron Metabolism Disorders

Interventions

DRUG

Erythropoietin

Intravenous injection of 50 U/kg of erythropoietin

DRUG

Placebo

Intravenous injection of equivalent volume of saline serum

Sponsors & Collaborators

  • Rennes University Hospital

    lead OTHER

Principal Investigators

  • Fabrice LAINE, MD · Rennes University Hospital

  • Bruno LAVIOLLE, MD · RennesUniversity Hospital

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-03-31
Primary Completion
2008-11-30
Completion
2009-02-28

Countries

  • France

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00687518 on ClinicalTrials.gov